The concern of generic rivalry has long loomed above copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the prospects of related medicinal stakes. While early times saw substantial gains, the intellectual property lapse has created the path for less expensive copies, possibly reducing profitability and posing a genuine danger f